Valneva SE (NASDAQ:VALN) Short Interest Down 34.6% in December

Valneva SE (NASDAQ:VALN) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 15,900 shares, a decrease of 34.6% from the December 15th total of 24,300 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 38,300 shares, the days-to-cover ratio is presently 0.4 days.

Valneva Trading Down 2.2 %

Shares of Valneva stock opened at $4.44 on Tuesday. The firm has a market cap of $360.80 million, a PE ratio of -34.15 and a beta of 1.93. Valneva has a 1 year low of $3.62 and a 1 year high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock has a fifty day moving average price of $4.41 and a 200-day moving average price of $5.93.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC lifted its stake in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 at the end of the most recent quarter. 11.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their target price on shares of Valneva from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, October 11th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.